Andrén, Per https://orcid.org/0000-0003-1358-0166
Jakubovski, Ewgeni https://orcid.org/0000-0001-8546-5330
Murphy, Tara L. https://orcid.org/0000-0003-1759-3562
Woitecki, Katrin
Tarnok, Zsanett https://orcid.org/0000-0002-2493-0232
Zimmerman-Brenner, Sharon https://orcid.org/0000-0001-6681-2958
van de Griendt, Jolande https://orcid.org/0000-0003-2548-3339
Debes, Nanette Mol https://orcid.org/0000-0003-0279-1865
Viefhaus, Paula https://orcid.org/0000-0003-4929-8138
Robinson, Sally https://orcid.org/0000-0001-8239-4354
Roessner, Veit https://orcid.org/0000-0002-1873-7081
Ganos, Christos https://orcid.org/0000-0001-8077-8530
Szejko, Natalia https://orcid.org/0000-0001-6160-9221
Müller-Vahl, Kirsten R. https://orcid.org/0000-0002-7181-7419
Cath, Danielle https://orcid.org/0000-0001-9539-4118
Hartmann, Andreas https://orcid.org/0000-0002-0335-984X
Verdellen, Cara https://orcid.org/0000-0002-3436-6903
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 9 March 2021
Accepted: 7 July 2021
First Online: 27 July 2021
Declarations
:
: CG received research grants from the VolkswagenStiftung (Freigeist Fellowship) and the German Parkinson Society and was also supported by the Deutsche Forschungsgemeinschaft (GA2031/1-1 and GA2031/1-2) and Actelion Pharmaceuticals. He also received financial support/honoraria to speak at meetings by Actelion pharmaceuticals and as ad hoc advisory board for Lundbeck. AH has received consultancy honoraria from Lundbeck and Noema Pharma. He has received research grants from the Association Française pour le Syndrome Gilles de la Tourette (AFSGT). DC received grant from the EU (TS EUROTRAIN), grant nr. 316978), several grants from ZONMW and MAGW (the Netherlands), from TSA-USA (2008), from Sunovion (DS028 (2019). From Espria fonds, Drenthe, the Netherlands. She has received speakers’ fees from ECNP, Psyfar, Benecke, Pfizer. KMV has received financial or material research support from the EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), the German Research Foundation (DFG: GZ MU 1527/3-1), the German Ministry of Education and Research (BMBF: 01KG1421), the National Institute of Mental Health (NIMH), the Tourette Gesellschaft Deutschland e.V., the Else-Kröner-Fresenius-Stiftung, and Abide Therapeutics, Almirall Hermal GmbH, GW pharmaceuticals, Lundbeck, Syneos Health, and Therapix Biosciences Ltd.She has received consultant's honoraria from Abide Therapeutics, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., Eurox Deutschland GmbH, Global Praxis Group Limited, Lundbeck, Resalo Vertrieb GmbH, Sanity Group, Synendos Therapeutics AG, and Tilray. She is/was a consultant or advisory board member for Abide Therapeutics, The Academy of Medical Cannabis Limited, Alirio, Aphria Deutschland GmbH, CannaMedical Pharma GmbH, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, CTC Communications Corp., Leafly Deutschland GmbH, Lundbeck, Nomovo Pharm, Nuvelution TS Pharma Inc., Resalo Vertrieb GmbH, Sanity Group, Syqe Medical Ltd., Therapix Biosciences Ltd., Tilray, Wayland Group, Zynerba Pharmaceuticals, and CTC Communications Corporation. She has received speaker’s fees from Aphria Deutschland GmbH, Cogitando GmbH, Emalex, Eurox group, Ever pharma GmbH, PR Berater, Tilray, and Wayland Group. She has received royalties from Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, Elsevier, and Kohlhammer. She holds shares of Nomovo Pharm. She served as a Guest Editor for Frontiers in Neurology on the research topic “The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects” and is Associate Editor for “Cannabis and Cannabinoid Research”, Editorial Board Member for “Medical Cannabis and Cannabinoids” and “MDPI-Reports”, and scientific board member for “Zeitschrift für Allgemeinmedizin”. VR has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medicine Pharma, and support for research from Shire Pharmaceuticals and Novartis. He has carried out clinical trials in cooperation with the Novartis, Shire, Servier and Otsuka companies. All other authors have no conflicts to declare.